United States Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market to Reach US$ 64.09 Billion by 2033 as Novel Therapies Accelerate Adoption, North America Holds 42% Share, Pfizer, Alnylam Pharmaceuticals & BridgeBio Pharma Lead

The Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market reached USD 5.85 billion in 2025 and is projected to witness exceptional growth by reaching up to USD 64.09 billion by 2033. The Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market is expected to exhibit a CAGR of 35.3% during the forecast period 2026-2033, driven by increasing disease awareness, improvements in diagnostic capabilities, and the growing availability of novel disease-modifying therapies across major healthcare markets worldwide.

Download your exclusive sample report today (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/transthyretin-amyloid-cardiomyopathy-market?sindhuri

Growth is strongly supported by rising diagnosis rates among aging populations and increasing demand for targeted therapies addressing both hereditary and wild-type ATTR-CM. Expanding adoption of transthyretin stabilizers, RNA interference (RNAi) therapies, and emerging gene-silencing approaches is significantly improving patient outcomes and slowing disease progression. Advances in non-invasive imaging technologies, biomarker-based diagnostics, and precision medicine approaches are further enhancing early detection and treatment accessibility.

Additionally, growing investments in rare disease research, increasing clinical trial activity, and expanding patient access programs are major growth drivers, as pharmaceutical companies continue to accelerate the development of innovative therapeutics. Rising prevalence of heart failure among elderly populations, improved physician awareness, and greater recognition of amyloidosis-related conditions are further contributing to market expansion. Ongoing innovation in next-generation transthyretin stabilizers, RNA-targeted therapies, gene-editing technologies, and combination treatment approaches is strengthening the long-term growth outlook of the market.

North America remains the dominant region, supported by strong healthcare infrastructure, early adoption of advanced therapies, robust reimbursement frameworks, and the presence of leading pharmaceutical companies. Europe is witnessing steady growth due to increasing awareness of rare cardiovascular disorders and expanding access to specialized treatment centers. Asia-Pacific is expected to emerge as the fastest-growing region owing to improving healthcare infrastructure, rising healthcare expenditure, growing awareness regarding amyloidosis, and increasing investments in rare disease diagnostics and therapeutics across countries such as China, India, and Japan.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market: Competitive Intelligence
Pfizer Inc., Alnylam Pharmaceuticals, BridgeBio Pharma, Ionis Pharmaceuticals, AstraZeneca, Intellia Therapeutics, Novo Nordisk, Prothena Corporation plc, Neurimmune AG, and Eidos Therapeutics are among the major global players shaping the competitive landscape of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market. These companies are focused on developing advanced transthyretin stabilizers, RNAi therapies, gene-silencing technologies, and next-generation disease-modifying treatments for patients suffering from hereditary and wild-type ATTR-CM.

The ATTR-CM market is primarily driven by increasing disease prevalence, improved diagnostic rates, and the growing demand for therapies capable of slowing disease progression and reducing cardiovascular complications. Expanding utilization of precision medicine approaches, enhanced physician awareness, and favorable regulatory support for rare diseases are further strengthening global market adoption.

Competitive differentiation is driven by therapeutic efficacy, safety profiles, dosing convenience, duration of clinical benefit, and affordability. Pfizer maintains a strong position through its tafamidis franchise, while Alnylam Pharmaceuticals is expanding its presence through RNAi-based therapies. BridgeBio Pharma is strengthening the market through next-generation transthyretin stabilizers, and several emerging companies are advancing gene-editing and amyloid-clearance approaches. Strategic priorities include accelerating clinical development programs, expanding access in emerging markets, integrating precision diagnostics, and developing combination therapies capable of delivering superior long-term outcomes.

Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/transthyretin-amyloid-cardiomyopathy-market?sindhuri

Recent Key Developments - United States & North America
✅ June 2025: Growing awareness and improved diagnostic capabilities for transthyretin amyloid cardiomyopathy (ATTR-CM) accelerated patient identification across the United States, supporting increased adoption of disease-modifying therapies and specialized cardiac care programs.
✅ May 2025: Expansion of precision medicine initiatives and broader access to genetic testing strengthened early detection of hereditary and wild-type ATTR-CM, enhancing treatment outcomes and disease management across North America.
✅ 2025: Rising investments in rare disease research and strategic collaborations among pharmaceutical companies and healthcare institutions significantly advanced the development of next-generation ATTR-CM therapies and patient support programs throughout the region.

Recent Key Developments - Japan & Asia-Pacific
✅ July 2025: Increasing prevalence of age-related cardiovascular disorders and expanding clinical awareness drove greater diagnosis and treatment uptake for ATTR-CM across Japan and major Asia-Pacific markets.
✅ Early 2026: Growth in specialized amyloidosis centers and improved access to advanced imaging and biomarker technologies accelerated the detection of transthyretin amyloid cardiomyopathy in Asia-Pacific.
✅ 2025: Government initiatives supporting rare disease management and precision healthcare promoted research activities and strengthened the development pipeline for innovative ATTR-CM therapies across the region.

Recent Key Developments - Product & Technology Innovation
✅ 2025: Advanced Transthyretin Stabilizers: Continued progress in transthyretin-stabilizing therapies improved disease progression control and enhanced survival outcomes for patients with ATTR-CM.
✅ Gene-Silencing and RNA-Based Therapies: Advancements in RNA interference (RNAi) and antisense oligonucleotide technologies expanded therapeutic possibilities by reducing transthyretin protein production and targeting the underlying cause of the disease.
✅ Precision Diagnostics and Digital Monitoring: Increasing adoption of nuclear imaging techniques, genetic screening, biomarker-based diagnostics, and remote patient monitoring solutions supported earlier diagnosis, personalized treatment strategies, and improved long-term management of ATTR-CM.

M&A / Strategic Activity
Recent strategic acquisitions, partnerships, and ecosystem developments shaping the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market:

Pfizer Inc. - Strengthening ATTR-CM therapeutic leadership
Pfizer has continued expanding its cardiovascular rare disease portfolio through strategic collaborations and commercial initiatives supporting the global adoption of tafamidis-based therapies for ATTR-CM, while enhancing physician awareness and diagnostic capabilities.

BridgeBio Pharma - Partnerships accelerating disease-modifying therapies
BridgeBio Pharma has pursued strategic partnerships and development collaborations to advance acoramidis and broaden access to next-generation transthyretin stabilizers for patients with ATTR-CM.

Alnylam Pharmaceuticals - Expansion in RNA interference ecosystem
Alnylam has strengthened collaborations with healthcare institutions and research organizations to support the development and commercialization of RNA interference therapies targeting transthyretin production for hereditary and wild-type ATTR-CM.

AstraZeneca and Ionis Pharmaceuticals - Advancing antisense therapeutics
AstraZeneca and Ionis have expanded their strategic partnership to accelerate the development of eplontersen and other RNA-targeted therapies aimed at addressing transthyretin-mediated diseases, including ATTR-CM.

Intellia Therapeutics - Gene-editing ecosystem development
Intellia Therapeutics continues to strengthen collaborations in CRISPR-based therapies, advancing investigational in vivo gene-editing approaches designed to provide durable treatment options for transthyretin amyloidosis patients.

New Product/Therapy Launches & Deployments
Recent innovations and deployments in the ATTR-CM space:

Pfizer Inc. - Tafamidis expansion across global markets
Pfizer has expanded access to tafamidis therapies, which remain the standard of care for ATTR-CM, supported by growing physician adoption and increasing diagnostic awareness.

BridgeBio Pharma - Acoramidis commercialization initiatives
BridgeBio has accelerated preparations for broader deployment of acoramidis, a next-generation transthyretin stabilizer designed to improve functional outcomes and quality of life in ATTR-CM patients.

Alnylam Pharmaceuticals - RNA silencing therapies
Alnylam continues advancing RNA interference therapies that suppress transthyretin production, offering potential disease-modifying approaches for hereditary transthyretin amyloidosis with cardiac involvement.

Ionis Pharmaceuticals - Eplontersen development progress
Ionis has expanded clinical development activities for eplontersen, targeting reduction of circulating transthyretin protein and addressing progressive manifestations of ATTR-related disease.

Intellia Therapeutics - Gene-editing therapeutic candidates
Intellia has advanced CRISPR/Cas9-based investigational therapies aimed at achieving long-term reduction of transthyretin protein production through one-time treatment approaches.

R&D & Technological Advancements
Next-generation transthyretin stabilizers
Research is focused on developing highly potent stabilizers capable of slowing disease progression and improving survival outcomes in both hereditary and wild-type ATTR-CM patients.

RNA interference and antisense technologies
Innovations in RNA-targeted therapeutics are enabling more effective suppression of transthyretin synthesis, expanding treatment possibilities beyond protein stabilization.

Gene-editing approaches for durable disease control
CRISPR-based technologies are being investigated as potentially transformative therapies capable of permanently reducing abnormal transthyretin production.

Earlier diagnosis through advanced imaging and biomarkers
The adoption of nuclear scintigraphy, cardiac MRI, genetic testing, and biomarker-based screening is improving early detection and enabling timely intervention.

Personalized medicine and precision diagnostics
Growing use of genomic profiling and disease subtype characterization is supporting individualized treatment strategies and optimized patient management.

Combination treatment strategies
Clinical research is increasingly evaluating combinations of stabilizers, silencers, and emerging therapies to maximize therapeutic benefits and delay disease progression.

Market Drivers & Emerging Trends
» Increasing prevalence of age-related and hereditary transthyretin amyloidosis is expanding the global patient population requiring treatment.
» Rising awareness among cardiologists and improvements in diagnostic pathways are enabling earlier detection of ATTR-CM.
» Strong clinical success of tafamidis and emerging disease-modifying therapies is accelerating market growth.
» Advancements in RNA interference, antisense oligonucleotides, and gene-editing technologies are transforming the treatment landscape.
» Growing investments in rare disease research and precision medicine are supporting innovation across the ATTR-CM ecosystem.
» Expansion of companion diagnostics and non-invasive imaging technologies is improving disease identification and patient stratification.
» Increasing healthcare expenditure and favorable regulatory incentives for orphan diseases are encouraging development of novel ATTR-CM therapies.
» Rising collaborations among pharmaceutical companies, biotechnology firms, and academic institutions are accelerating therapeutic innovation and commercialization.

Buy Now & Unlock 360° Market Intelligence:
https://www.datamintelligence.com/buy-now-page?report=transthyretin-amyloid-cardiomyopathy-market?sindhuri

Segments Covered in the Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market:
By Type
The market is segmented into wild-type ATTR-CM (62%) and familial (hereditary) ATTR-CM (38%). Wild-type ATTR-CM dominates the market owing to its higher prevalence among the aging population and increasing diagnosis rates supported by improved awareness and advanced imaging technologies. Familial (hereditary) ATTR-CM is witnessing steady growth due to the availability of genetic testing and expanding access to targeted therapies, particularly among patients with inherited transthyretin gene mutations.

By Drug Type
The market is segmented into transthyretin stabilizers (68%), RNAi therapy (22%), and others (10%). Transthyretin stabilizers account for the largest share due to their established clinical efficacy and widespread adoption as first-line treatment options for slowing disease progression. RNAi therapies are experiencing rapid growth driven by technological advancements and increasing approvals of gene-silencing therapies aimed at reducing transthyretin protein production. The others segment includes supportive therapies and emerging treatment approaches that are being explored in clinical development.

By Distribution Channel
The market is divided into hospital pharmacies (58%), retail pharmacies (27%), and online pharmacies (15%). Hospital pharmacies lead the segment as ATTR-CM therapies are predominantly prescribed and managed through specialized healthcare centers and hospitals with expertise in rare cardiovascular diseases. Retail pharmacies are expanding with growing outpatient treatment and improved availability of branded medications. Online pharmacies are witnessing increasing adoption owing to convenience, home delivery services, and expanding digital healthcare infrastructure.

By Region
North America - 42% Share
North America dominates the market due to the high prevalence of ATTR-CM, favorable reimbursement policies, increasing awareness among healthcare professionals, and the presence of leading pharmaceutical companies and advanced diagnostic capabilities in the United States and Canada.

Europe - 27% Share
Europe holds a significant share supported by growing recognition of rare cardiovascular disorders, improved access to innovative therapies, and strong healthcare systems across countries such as Germany, France, Italy, and the UK.

Asia-Pacific - 20% Share
Asia-Pacific is emerging as a high-growth region owing to increasing healthcare expenditure, expanding diagnostic capabilities, rising awareness of amyloidosis, and improving access to advanced therapies in countries including China, Japan, South Korea, and India.

Contact:
Fabian
DataM Intelligence 4market Research LLP 6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda,
Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology. Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.